Update on Adjuvant Analgesics in Advanced Illness
Note: Institutional group rates are available upon request.
Select type to purchase:
Funding Disclosure: No commercial funding has been accepted for the activity.
Russell K. Portenoy, MD
Chief Medical Officer, MJHS Hospice and Palliative Care, New York, NY
Executive Director, MJHS Institute for Innovation in Palliative Care, New York, NY
Professor of Neurology and Family and Social Medicine,
Albert Einstein College of Medicine, Bronx, NY
Purpose: The effective use of adjuvant analgesics is considered a best practice in the management of specific types of chronic pain experienced by populations with advanced illness, particularly cancer populations. This webinar will present the evidence in support of the efficacy and safety of the various drug classes that comprise the adjuvant analgesics and offer practical guidelines for the use of these drugs.
Why Do I Need to Know This?
Although opioids are highly effective across populations with advanced illness, a substantial proportion of patients, as many as one-third, are unable to achieve a favorable balance between analgesia and side effects. Poor responsiveness to opioids is more likely when chronic pain is related to neuropathic mechanisms. Bone pain and pain related to bowel obstruction also present clinical challenges. The use of adjuvant analgesics for neuropathic pain, bone pain, and pain due to bowel obstruction is evidence-based and should be understood by all clinicians who manage pain in populations with advanced illness.
- Discuss the approach to opioid pharmacotherapy in patients with pain that may be treated with adjuvant analgesics
- Describe the selection and dosing of first-line antidepressant and antiepileptic adjuvant analgesics
- Identify best practices in the treatment of neuropathic pain and bone pain
Target Audience: palliative care specialists, pain specialists, primary care providers, nurse practitioners, registered nurses, advanced practice nurses, registered nurses with a specialty in palliative care/hospice, allied health professionals, fellows, residents, and medical students.
Criteria for Successful Completion:
- Attendance at entire session
- Submission of completed evaluation form
- Successful completion of a posttest (70% for physicians, non-physicians, and nurses)
Continuing Education Credits: 1.0
Release Date: February 28, 2018
Continuing Education Accreditation:
Physicians: This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Medical Society of the State of New York (MSSNY) through the joint providership of MSSNY and the MJHS Institute for Innovation in Palliative Care. MSSNY is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses: MJHS Institute for Innovation in Palliative Care is an approved provider of continuing nursing education by The Alabama State Nurses Association, an accredited approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Individual: $25 (includes CME/CE certificate)
Russell K. Portenoy, MD, Faculty and Planner, has indicated a relationship with AstraZeneca Pharmaceuticals LP and Tabula Rasa for research support.
No other Planning Committee Member has any disclosures.
Planning Committee Members
Lara Dhingra, PhD
Colleen Fleming-Damon, PhDc, ANP-BC, ACHPN, FT
Myra Glajchen, DSW
Helena Knotkova, PhD
Russell K. Portenoy, MD
Karen Richards, PhD, EdS
Wini Schein, BA